Pharvaris NV Insider Confidence Signals Strong Oral B2 Antagonist Growth
Pharvaris NV insider holdings reveal confidence in its oral B2 antagonist launch, payer talks, and phased option vesting—highlighting low agency risk and upside potential for investors.
4 minutes to read